Biolojic Design's AI-Designed BD200 Shows Superior Anti-Tumor Activity in Preclinical Studies Targeting Dual Cancer Antigens
核心洞察
Biolojic Design (搜索) presented preclinical data for BD200 (搜索), the first multibody-drug conjugate that targets both Trop-2 (搜索) and Nectin-4 (搜索) antigens simultaneously using AI-designed antibody technology.
BD200 (搜索) demonstrated superior cellular uptake and cytotoxicity compared to approved drugs targeting either Trop-2 (搜索) or Nectin-4 (搜索) alone across multiple cancer types.
The drug showed strong anti-tumor activity in resistance settings where other antibody-drug conjugates were ineffective, with clinical trials expected to begin in the second half of 2026.
Biolojic Design (搜索) has unveiled promising preclinical data for BD200 (搜索), a first-in-class multibody-drug conjugate that represents a significant advancement in antibody-drug conjugate (ADC) technology. The data, presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, demonstrate BD200's superior anti-tumor properties compared to existing approved therapies targeting individual cancer antigens.
Novel AI-Designed Multibody Technology
BD200 (搜索) is built on Biolojic Design (搜索)'s proprietary multibody platform, which uses artificial intelligence to create antibodies that can conditionally bind to multiple targets while maintaining the natural format of a human IgG antibody. Unlike conventional bi-specific antibodies with fixed binding profiles, each arm of BD200 can bind to either Trop-2 (搜索) or Nectin-4 (搜索), two proteins that drive tumor progression, adhesion, and metastasis in various solid tumors.
"We're excited to share data from the first ever multibody-drug conjugate, which has the potential to transform ADC technology and, as our data suggest, lead to more efficacious and safer treatment," said Yanay Ofran, PhD, CEO and founder of Biolojic Design (搜索). "The unique ability of a multibody to adapt to the heterogeneity of tumor antigen expression makes it an ideal base for an ADC, potentially enhancing anti-tumor activity while reducing the amount of drug needed to dose."
Superior Performance Across Multiple Cancer Types
The preclinical data revealed BD200 (搜索)'s robust anti-tumor activity across diverse cancer models. The drug demonstrated strong anti-tumor responses in patient-derived xenografts of triple negative breast cancer (搜索), bladder, cervical and esophageal cancer (搜索), as well as gastric cancer (搜索) in cell line-derived xenograft models.
Notably, BD200 (搜索) showed superior uptake in a Trop-2 (搜索)/Nectin-4 (搜索) dual-expressing breast cancer cell line when compared to currently marketed antibodies and antibody-drug conjugates that bind to either Trop-2 or Nectin-4 alone. This enhanced uptake translated to improved cellular cytotoxicity compared to approved drugs targeting either antigen individually.
Overcoming Drug Resistance
One of BD200 (搜索)'s most significant advantages lies in its ability to overcome resistance mechanisms that limit other ADCs. The drug showed strong activity in tumor models derived from patients that were resistant to other ADCs. In mice bearing human tumors that developed resistance to other ADCs, BD200 led to deep regressions, even in larger tumors with volumes exceeding 2000mm³.
In cell lines resistant to ADCs that bind only to Nectin-4 (搜索), switching to BD200 (搜索) restored potent anti-tumor activity, highlighting the therapeutic potential of the dual-targeting approach.
Addressing Tumor Heterogeneity
The flexible targeting mechanism of BD200 (搜索) addresses a critical challenge in cancer treatment: tumor antigen expression heterogeneity. While both Trop-2 (搜索) and Nectin-4 (搜索) may be expressed by cancer cells, their expression levels can vary significantly between patients and even within individual tumors. BD200's ability to bind to either target helps overcome this heterogeneity while maintaining full avidity on cells, enabling more effective delivery of cytotoxic payload to tumors while reducing off-tumor and systemic toxicity.
According to Ofran, the combination of the multibody platform with Biolojic's designed linker/payload results in "a dramatically improved therapeutic index compared to other ADCs."
Clinical Development Timeline
BD200 (搜索) targets two proteins co-expressed in various solid tumors, including bladder, breast, lung and head and neck cancers. The company expects to initiate clinical trials for BD200 in the second half of 2026, marking a significant milestone for this novel therapeutic approach.
Biolojic Design (搜索)'s platform has already demonstrated clinical success, with the company's first AI-designed antibody currently in phase 2 clinical trials. The company focuses on autoimmune diseases and oncology, working to unlock validated pathways that address large unmet medical needs through partnerships with leading biopharmaceutical companies.